Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements

Eduardo Huarte, Pablo Sarobe, Jun Lu, Noelia Casares, Juan José Lasarte, Javier Dotor, Marta Ruiz, Jesús Prieto, Esteban Celis, Francisco Borrás-Cuesta

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: Many epitopes from tumor antigens recognized by CTLs can be poorly immunogenic. This low immunogenicity can be improved by carrying out amino acid replacements in their sequence. We have applied this strategy to enhance the immunogenicity of the HLA-A2-restricted CTL epitope CEA691 (IMIGVLVGV) from carcinoembryonic antigen (CEA), which is expressed by a wide variety of tumors. Experimental Design: Substituted peptides from CEA691 were synthesized and tested in HLA-A2-binding assays, and in recognition by CEA691-specific CTL. Selected peptides were used to induce CTL responses in vivo in HLA-A2Kb transgenic mice and in vitro with human cells. Results: Our experiments afforded several peptides with enhanced binding and/or recognition by CTL specific of CEA691. However, when HLA-A2Kb mice were immunized with these peptides only a few induced a CTL response that cross-reacted with CEA691. Additional replacement of their NH2-terminal amino acid by Y (tyrosine) afforded peptides YMIGMLVGV and YMIGVLLGV with enhanced in vivo and in vitro immunogenicity than CEA691. Indeed, they activated a greater number of precursor cells that recognized CEA691-pulsed cells and tumor cells expressing CEA. Conclusions: Our results widen the possibility of treating CEA-expressing tumors with enhanced efficacy.

Original languageEnglish (US)
Pages (from-to)2336-2344
Number of pages9
JournalClinical Cancer Research
Volume8
Issue number7
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Carcinoembryonic Antigen
Epitopes
Amino Acids
Peptides
HLA-A2 Antigen
Neoplasms
Neoplasm Antigens
Transgenic Mice
Tyrosine
Research Design
Cell Count
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Huarte, E., Sarobe, P., Lu, J., Casares, N., Lasarte, J. J., Dotor, J., ... Borrás-Cuesta, F. (2002). Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Clinical Cancer Research, 8(7), 2336-2344.

Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. / Huarte, Eduardo; Sarobe, Pablo; Lu, Jun; Casares, Noelia; Lasarte, Juan José; Dotor, Javier; Ruiz, Marta; Prieto, Jesús; Celis, Esteban; Borrás-Cuesta, Francisco.

In: Clinical Cancer Research, Vol. 8, No. 7, 01.01.2002, p. 2336-2344.

Research output: Contribution to journalArticle

Huarte, E, Sarobe, P, Lu, J, Casares, N, Lasarte, JJ, Dotor, J, Ruiz, M, Prieto, J, Celis, E & Borrás-Cuesta, F 2002, 'Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements', Clinical Cancer Research, vol. 8, no. 7, pp. 2336-2344.
Huarte E, Sarobe P, Lu J, Casares N, Lasarte JJ, Dotor J et al. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Clinical Cancer Research. 2002 Jan 1;8(7):2336-2344.
Huarte, Eduardo ; Sarobe, Pablo ; Lu, Jun ; Casares, Noelia ; Lasarte, Juan José ; Dotor, Javier ; Ruiz, Marta ; Prieto, Jesús ; Celis, Esteban ; Borrás-Cuesta, Francisco. / Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 7. pp. 2336-2344.
@article{0aa0393237914f5a90793e6891a0feed,
title = "Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements",
abstract = "Purpose: Many epitopes from tumor antigens recognized by CTLs can be poorly immunogenic. This low immunogenicity can be improved by carrying out amino acid replacements in their sequence. We have applied this strategy to enhance the immunogenicity of the HLA-A2-restricted CTL epitope CEA691 (IMIGVLVGV) from carcinoembryonic antigen (CEA), which is expressed by a wide variety of tumors. Experimental Design: Substituted peptides from CEA691 were synthesized and tested in HLA-A2-binding assays, and in recognition by CEA691-specific CTL. Selected peptides were used to induce CTL responses in vivo in HLA-A2Kb transgenic mice and in vitro with human cells. Results: Our experiments afforded several peptides with enhanced binding and/or recognition by CTL specific of CEA691. However, when HLA-A2Kb mice were immunized with these peptides only a few induced a CTL response that cross-reacted with CEA691. Additional replacement of their NH2-terminal amino acid by Y (tyrosine) afforded peptides YMIGMLVGV and YMIGVLLGV with enhanced in vivo and in vitro immunogenicity than CEA691. Indeed, they activated a greater number of precursor cells that recognized CEA691-pulsed cells and tumor cells expressing CEA. Conclusions: Our results widen the possibility of treating CEA-expressing tumors with enhanced efficacy.",
author = "Eduardo Huarte and Pablo Sarobe and Jun Lu and Noelia Casares and Lasarte, {Juan Jos{\'e}} and Javier Dotor and Marta Ruiz and Jes{\'u}s Prieto and Esteban Celis and Francisco Borr{\'a}s-Cuesta",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "8",
pages = "2336--2344",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements

AU - Huarte, Eduardo

AU - Sarobe, Pablo

AU - Lu, Jun

AU - Casares, Noelia

AU - Lasarte, Juan José

AU - Dotor, Javier

AU - Ruiz, Marta

AU - Prieto, Jesús

AU - Celis, Esteban

AU - Borrás-Cuesta, Francisco

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Purpose: Many epitopes from tumor antigens recognized by CTLs can be poorly immunogenic. This low immunogenicity can be improved by carrying out amino acid replacements in their sequence. We have applied this strategy to enhance the immunogenicity of the HLA-A2-restricted CTL epitope CEA691 (IMIGVLVGV) from carcinoembryonic antigen (CEA), which is expressed by a wide variety of tumors. Experimental Design: Substituted peptides from CEA691 were synthesized and tested in HLA-A2-binding assays, and in recognition by CEA691-specific CTL. Selected peptides were used to induce CTL responses in vivo in HLA-A2Kb transgenic mice and in vitro with human cells. Results: Our experiments afforded several peptides with enhanced binding and/or recognition by CTL specific of CEA691. However, when HLA-A2Kb mice were immunized with these peptides only a few induced a CTL response that cross-reacted with CEA691. Additional replacement of their NH2-terminal amino acid by Y (tyrosine) afforded peptides YMIGMLVGV and YMIGVLLGV with enhanced in vivo and in vitro immunogenicity than CEA691. Indeed, they activated a greater number of precursor cells that recognized CEA691-pulsed cells and tumor cells expressing CEA. Conclusions: Our results widen the possibility of treating CEA-expressing tumors with enhanced efficacy.

AB - Purpose: Many epitopes from tumor antigens recognized by CTLs can be poorly immunogenic. This low immunogenicity can be improved by carrying out amino acid replacements in their sequence. We have applied this strategy to enhance the immunogenicity of the HLA-A2-restricted CTL epitope CEA691 (IMIGVLVGV) from carcinoembryonic antigen (CEA), which is expressed by a wide variety of tumors. Experimental Design: Substituted peptides from CEA691 were synthesized and tested in HLA-A2-binding assays, and in recognition by CEA691-specific CTL. Selected peptides were used to induce CTL responses in vivo in HLA-A2Kb transgenic mice and in vitro with human cells. Results: Our experiments afforded several peptides with enhanced binding and/or recognition by CTL specific of CEA691. However, when HLA-A2Kb mice were immunized with these peptides only a few induced a CTL response that cross-reacted with CEA691. Additional replacement of their NH2-terminal amino acid by Y (tyrosine) afforded peptides YMIGMLVGV and YMIGVLLGV with enhanced in vivo and in vitro immunogenicity than CEA691. Indeed, they activated a greater number of precursor cells that recognized CEA691-pulsed cells and tumor cells expressing CEA. Conclusions: Our results widen the possibility of treating CEA-expressing tumors with enhanced efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0035992407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035992407&partnerID=8YFLogxK

M3 - Article

C2 - 12114438

AN - SCOPUS:0035992407

VL - 8

SP - 2336

EP - 2344

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -